Kristensen O, Hansen E
Acta Neurol Scand. 1977 Sep;56(3):274-6. doi: 10.1111/j.1600-0404.1977.tb01434.x.
The dopaminergic agonist bromocriptine in doses of 2.5-40 mg was compared with placebo in a double-blind cross-over study (12 + 12 weeks) in 11 Parkinson patients in whom bothering dyskinesia occurring after prolonged levodopa treatment limited in the levodopa dose to a level, where Parkinson symptoms still were present to an unsatisfactory degree. On the basis of changes in rating scales and the patients' preference, bromocriptine was significantly superior to placebo. Dyskinesia, occurring during bromocriptine treatment in 9 of 11 patients, disappeared within the period of study in 6 patients after dose reduction without changes in Parkinson disability scores to placebo level. Bromocriptine seem to be of value in cases where the balance between minimal dyskinesia and Parkinson symptoms is impossible to obtain with levodopa treatment alone.
在一项双盲交叉研究（12 + 12周）中，对11例帕金森病患者使用剂量为2.5 - 40毫克的多巴胺能激动剂溴隐亭与安慰剂进行了比较。这些患者在长期左旋多巴治疗后出现了烦人的运动障碍，左旋多巴剂量被限制在一个水平，此时帕金森症状仍存在且程度不尽人意。基于评分量表的变化和患者的偏好，溴隐亭明显优于安慰剂。11例患者中有9例在溴隐亭治疗期间出现运动障碍，其中6例在剂量减少后研究期间运动障碍消失，帕金森病残疾评分未降至安慰剂水平。在仅用左旋多巴治疗无法实现最小运动障碍与帕金森症状之间平衡的情况下，溴隐亭似乎具有价值。
